JP2019535826A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535826A5 JP2019535826A5 JP2019547229A JP2019547229A JP2019535826A5 JP 2019535826 A5 JP2019535826 A5 JP 2019535826A5 JP 2019547229 A JP2019547229 A JP 2019547229A JP 2019547229 A JP2019547229 A JP 2019547229A JP 2019535826 A5 JP2019535826 A5 JP 2019535826A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- therapeutic
- carbon atoms
- linear
- branched alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 125000004432 carbon atom Chemical group C* 0.000 claims 9
- 230000000069 prophylactic effect Effects 0.000 claims 9
- 230000001225 therapeutic effect Effects 0.000 claims 9
- 208000024172 Cardiovascular disease Diseases 0.000 claims 7
- 208000019693 Lung disease Diseases 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 6
- 102100031126 6-phosphogluconolactonase Human genes 0.000 claims 4
- 108010029731 6-phosphogluconolactonase Proteins 0.000 claims 4
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 claims 4
- 208000002815 pulmonary hypertension Diseases 0.000 claims 4
- 229940124530 sulfonamide Drugs 0.000 claims 4
- 150000003456 sulfonamides Chemical group 0.000 claims 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 3
- 125000002252 acyl group Chemical group 0.000 claims 3
- 239000004202 carbamide Substances 0.000 claims 3
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- 239000000460 chlorine Substances 0.000 claims 3
- 230000002526 effect on cardiovascular system Effects 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 239000011737 fluorine Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 3
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims 2
- 201000003076 Angiosarcoma Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims 2
- 238000009125 cardiac resynchronization therapy Methods 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000013078 crystal Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical group NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 claims 2
- 230000002861 ventricular Effects 0.000 claims 2
- CYKYBWRSLLXBOW-UHFFFAOYSA-N (3alpha,5alpha)-3,21-Dihydroxypregnan-20-one Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)C(=O)CO)C4C3CCC21 CYKYBWRSLLXBOW-UHFFFAOYSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical group NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000032781 Diabetic cardiomyopathy Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000034827 Neointima Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000008188 Timothy syndrome Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000002170 aldosterone antagonist Substances 0.000 claims 1
- 229940083712 aldosterone antagonist Drugs 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 229940097320 beta blocking agent Drugs 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000000496 cardiotonic agent Substances 0.000 claims 1
- 230000003177 cardiotonic effect Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 229940030606 diuretics Drugs 0.000 claims 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 claims 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims 1
- 230000002182 neurohumoral effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000008719 thickening Effects 0.000 claims 1
- 229940124549 vasodilator Drugs 0.000 claims 1
- 239000003071 vasodilator agent Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662422929P | 2016-11-16 | 2016-11-16 | |
| US62/422,929 | 2016-11-16 | ||
| PCT/US2017/061741 WO2018093856A1 (en) | 2016-11-16 | 2017-11-15 | Inhibitors of glucose-6-phosphate dehydrogenase for treating cardiovascular and pulmonary conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019535826A JP2019535826A (ja) | 2019-12-12 |
| JP2019535826A5 true JP2019535826A5 (https=) | 2020-12-24 |
Family
ID=62145797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019547229A Pending JP2019535826A (ja) | 2016-11-16 | 2017-11-15 | 心血管疾患及び肺疾患を治療するためのグルコース−６−リン酸デヒドロゲナーゼの阻害剤 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US11185552B2 (https=) |
| EP (1) | EP3542160B1 (https=) |
| JP (1) | JP2019535826A (https=) |
| WO (1) | WO2018093856A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10246711B2 (en) | 2016-11-16 | 2019-04-02 | Rakhee Gupte | RNAi inhibitors of glucose-6-phosphate dehydrogenase for treating cardiovascular and pulmonary conditions |
| US12014835B2 (en) | 2020-02-19 | 2024-06-18 | Vanderbilt University | Methods for evaluating therapeutic benefit of combination therapies |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60025526T2 (de) | 1999-11-16 | 2006-08-24 | Genentech, Inc., South San Francisco | Elisa für vegf |
| WO2002085297A2 (en) * | 2001-04-24 | 2002-10-31 | East Carolina University | Compositions & formulations with a non-glucocorticoid steroid &/or a ubiquinone & kit for treatment of respiratory & lung disease |
| KR20060054233A (ko) | 2006-04-07 | 2006-05-22 | 박상봉 | 액정디스플레이용 보강패널 및 그 제조방법 |
| WO2007117048A1 (en) * | 2006-04-10 | 2007-10-18 | Seoul National University Industry Foundation | Inhibitors against g6pd enzyme for treating and preventing oxidative stress and/or inflammatory related diseases and method for screening the same |
| EP2101567A4 (en) * | 2007-01-18 | 2010-04-21 | Univ Utah Res Found | COMPOSITIONS AND METHODS FOR DETECTING, TREATING OR PREVENTING REDUCED STRESS |
| WO2011127465A2 (en) * | 2010-04-09 | 2011-10-13 | The Research Foundation Of The State University Of New York | Ship inhibitors and uses thereof |
| PL2709631T3 (pl) | 2011-05-20 | 2017-07-31 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Antagoniści receptora cb1 |
-
2017
- 2017-11-15 WO PCT/US2017/061741 patent/WO2018093856A1/en not_active Ceased
- 2017-11-15 EP EP17872327.6A patent/EP3542160B1/en active Active
- 2017-11-15 US US16/349,676 patent/US11185552B2/en active Active
- 2017-11-15 JP JP2019547229A patent/JP2019535826A/ja active Pending
-
2021
- 2021-10-20 US US17/505,961 patent/US20220040202A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017524704A5 (https=) | ||
| JP2019094345A5 (https=) | ||
| JP2013528655A5 (https=) | ||
| JP2016500111A5 (https=) | ||
| EA031183B1 (ru) | Способы улучшения функции диафрагмы | |
| JP2013532652A5 (https=) | ||
| RU2018120242A (ru) | Хинолиновые соединения, способы их получения и их применения в качестве лекарственного средства, ингибирующего транспортер уратов | |
| JP2014532726A5 (https=) | ||
| JP2016510785A5 (https=) | ||
| JP2019535826A5 (https=) | ||
| JP2011519845A5 (https=) | ||
| JP2022550221A5 (https=) | ||
| RU2013130019A (ru) | Новые производные азетидина в качестве модуляторов рецептора сфингозин 1-фосфата (s1p) | |
| JP2006514051A (ja) | 慢性心不全の治療 | |
| JP2020520374A5 (https=) | ||
| JP2015533128A5 (https=) | ||
| WO2024138190A8 (en) | Crystalline forms of a lpa1 antagonist | |
| JP2005529110A5 (https=) | ||
| CN103998428B (zh) | 二苯基甲基哌嗪衍生物及使用该衍生物的医药组合物 | |
| Ginks et al. | Unsuspected coronary artery disease as cause of chronic atrioventricular block in middle age. | |
| RU2013130023A (ru) | Новые производные пиридина в качестве модуляторов рецептора сфингозин 1-фосфата (s1p) | |
| JPH05208993A (ja) | 虚血治療用製薬組成物 | |
| EP4108240A3 (en) | Benzimidazole derivatives for treatment and/or prevention of diseases and disorders mediated by nlrp3 | |
| BRPI0610818A2 (pt) | uso de derivados de rapamicina para o tratamento e/ou para a prevenção de distúrbios cardiovasculares | |
| JP2023532134A5 (https=) |